Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2012

01-05-2012 | Original Article

Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy

Authors: Divi Cornec, Adrian Tempescul, Solène Querellou, Pascal Hutin, Jacques-Olivier Pers, Christophe Jamin, Boutahar Bendaoud, Christian Berthou, Yves Renaudineau, Pierre Youinou

Published in: Annals of Hematology | Issue 5/2012

Login to get access

Abstract

The potential predictive value of tumor bulk, genetic, and immunological variants in patients with low-grade non-Hodgkin's lymphoma to respond to treatment with rituximab (RTX) monotherapy was evaluated. Thus, the value of assessing the effect of 18-fluoro-desoxy-d-glucose (FDG) uptake on PET scan, polymorphisms in Fc gamma receptor (FcγR) IIIa-158, FcγRIIa-131, and C1qA-276 genes in predicting the response to treatment were evaluated in 50 low-grade non-Hodgkin's lymphoma patients. The influence of RTX pharmacokinetics, plasma levels of the B cell-activating factor (BAFF), and human antichimeric antibodies was also investigated. The therapeutic response was evaluated 10 weeks after treatment using revised Cheson's criteria. Lower maximal standardized uptake values (SUVmax) at baseline were predictive of complete response. FcγRIIIa-158 polymorphism was also associated with complete response to RTX confirming previous findings, whereas polymorphisms in the FcγRIIa-131 and C1qA-276 genes were not. Lower blood levels of RTX were observed in males, but the effectiveness of RTX in males and females was the same. BAFF was not detectable in plasma before or after treatment, and no patients developed human antichimeric antibodies. Low-grade non-Hodgkin's lymphoma patients with a low SUVmax at baseline and an FcγRIIIa-158 V/V genotype generally had a complete response to RTX.
Literature
1.
Maloney DG, Grillo-López AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188–2195PubMed
2.
Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42–51PubMedCrossRef
3.
Renaudineau Y, Devauchelle-Pensec V, Hanrotel C, Pers JO, Saraux A, Youinou P (2009) Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. Joint Bone Spine 76:458–463PubMedCrossRef
4.
Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520–535PubMedCrossRef
5.
Dall’Ozzo S, Tartas S, Paintaud G et al (2004) Rituximab-dependent cytotoxicity by NK cells: influence of FcγRIIIa polymorphism on the concentration–effect relationship. Cancer Res 64:4664–4669PubMedCrossRef
6.
Van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB (2006) Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cell cytotoxicity. Clin Cancer Res 12:4027–4035PubMedCrossRef
7.
Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant B cells. Cancer Immunol Immunother 48:673–683PubMedCrossRef
8.
Cartron G, Dacheux L, Salles G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in Fc-gamma receptor IIIa gene. Blood 99:754–758PubMedCrossRef
9.
Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947PubMedCrossRef
10.
Racila E, Link BK, Weng W et al (2008) A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 14:6697–6703PubMedCrossRef
11.
Berinstein NL, Grillo-López AJ, White CA et al (1998) Association of serum rituximab concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9:995–1001PubMedCrossRef
12.
Davis TA, Grillo-López AJ, White CA et al (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18:3135–3143PubMed
13.
Novak AJ, Grote DM, Stenson M et al (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin's lymphoma: correlation with disease activity and patient outcome. Blood 104:2247–2253PubMedCrossRef
14.
Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465–475PubMedCrossRef
15.
Pers J, Devauchelle V, Daridon C et al (2007) BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 56:1464–1477PubMedCrossRef
16.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin's Staging Classification. Cancer Res 31:1860–1861PubMed
17.
Solal-Céligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265PubMedCrossRef
18.
Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586PubMedCrossRef
19.
Cragg MS, Bayne MB, Tutt AL et al (2004) A new anti-Id antibody capable of binding rituximab on the surface of lymphoma cells. Blood 104:2540–2542PubMedCrossRef
20.
Saito Y, Miyagawa Y, Onda K et al (2008) BAFF inhibits CD20-mediated and BCR-mediated apoptosis in human B cells. Immunology 125:570–590PubMedCrossRef
21.
22.
Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 15:42–52PubMedCrossRef
23.
Teeling JL, French RR, Cragg MS et al (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphoma. Blood 104:1793–1800PubMedCrossRef
24.
Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91:522–529PubMed
25.
Le Dortz L, De Guibert S, Bayat S et al (2010) Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 37:2307–2314PubMedCrossRef
26.
Cazaentre T, Morschhauser F, Bermandel M et al (2010) Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:494–504PubMedCrossRef
27.
Hatjiharissi E, Xu L, Santos DD et al (2007) Increased NK cell expression of CD16, augmented binding and ADCC activity of rituximab among individuals expressing the FcγRIIIa-158V/V and V/F polymorphism. Blood 110:2561–2564PubMedCrossRef
28.
Wu J, Edberg JC, Redecha PB et al (1997) A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100:1059–1070PubMedCrossRef
29.
Anolik JH, Campbell D, Felgar RE et al (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455–459PubMedCrossRef
30.
Mitroviç Z, Aurer I, Radman I, Ajdukoviç R, Sertiç J, Labar B (2007) FcγRIIIa and FcγRIIa polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica 92:998–999PubMedCrossRef
31.
Carlotti E, Palumbo GA, Oldani E et al (2007) FcγRIIIa and FcγRIIa polymorphisms do not predict clinical outcome of follicular NHL patients treated with sequential CHOP and rituximab. Haematologica 92:1127–1130PubMedCrossRef
32.
Weng WK, Levy R (2009) Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma 50:723–727PubMedCrossRef
33.
Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M (2008) Evidence for linkage disequilibrium between FcγRIIIa-V158F and FcγRIIa-H131R polymorphisms in White patients, and for an FcγRIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 26:5489–5491PubMedCrossRef
34.
Di Gaetano N, Cittera E, Nota R et al (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581–1587PubMed
35.
Nielsen CH, Fischer EM, Leslie RG (2000) The role of complement in the acquired immune response. Immunology 100:4–12PubMedCrossRef
36.
Uchida J, Hamaguchi Y, Oliver JA et al (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199:1659–1669PubMedCrossRef
37.
Tobinai K, Igarashi T, Itoh K et al (2004) Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 15:821–830PubMedCrossRef
38.
Novak AJ, Slager SL, Fredericksen ZS et al (2009) Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 69:4217–4224PubMedCrossRef
Metadata
Title
Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy
Authors
Divi Cornec
Adrian Tempescul
Solène Querellou
Pascal Hutin
Jacques-Olivier Pers
Christophe Jamin
Boutahar Bendaoud
Christian Berthou
Yves Renaudineau
Pierre Youinou
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 5/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-011-1369-y

Other articles of this Issue 5/2012

Annals of Hematology 5/2012 Go to the issue

Letter to the Editor

Quantification of plasma Epstein–Barr virus DNA for assessing treatment response in a patient with plasmablastic lymphoma

Original Article

Single nucleotide polymorphism of Wilms’ tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia

Original Article

Early engraftment of G-CSF-primed allogeneic bone marrow transplantation in pediatric patients regardless of donor–recipient weight differences

Original Article

Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study

Letter to the Editor

High hyperdiploid acute lymphoblastic leukemia in adults shows clonal heterogeneity and chromosomal instability at diagnosis and during the course of the disease

Letter to the Editor

Reduced intensity conditioning allogeneic hematopoietic stem cell transplant could be beneficial to angioimmunoblastic T-cell lymphoma patients with hemophagocytic lymphohistiocytosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits